User:Ann Taylor/GLP-1 agonists
From Proteopedia
< User:Ann Taylor(Difference between revisions)
(New page: ==GLP-1 agonists== <StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''> Glucagon-like peptide agonists (GLP) are used to treat type 2 diabe...) |
|||
| (6 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
==GLP-1 agonists== | ==GLP-1 agonists== | ||
| - | <StructureSection load=' | + | <StructureSection load='5NX2' size='340' side='right' caption='GLP-1 bound to receptor complex'> |
| - | + | ||
| - | + | ||
| + | <scene name='10/1043704/Glp-1_peptide/1'>Glucagon-like peptide agonists</scene> (GLP) are used to treat type 2 diabetes and obesity <ref>PMID:38639549</ref>. They GLP-1 agonists bind to the GLP receptor. | ||
| + | The GLP receptor is a G-protein coupled receptor. Its secondary structure is highlighted in <scene name='10/1043704/Glpr_secondary/1'>this view</scene>. The hydrophobic residues are shown in grey and the polar residues are shown in magenta in <scene name='10/1043704/Glpr_hydrophobic_hydrophilic/1'>this view</scene>. | ||
</StructureSection> | </StructureSection> | ||
| + | |||
== References == | == References == | ||
<references/> | <references/> | ||
Current revision
GLP-1 agonists
| |||||||||||
References
- ↑ Drake T, Landsteiner A, Langsetmo L, MacDonald R, Anthony M, Kalinowski C, Ullman K, Billington CJ, Kaka A, Sultan S, Wilt TJ. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Systematic Review and Network Meta-analysis for the American College of Physicians. Ann Intern Med. 2024 Apr 19. PMID:38639549 doi:10.7326/M23-1490
